Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Rapid Dose Therapeutics's operating assets for the quarter that ended in Nov. 2025 was $2.62 Mil. Rapid Dose Therapeutics's operating liabilities for the quarter that ended in Nov. 2025 was $3.11 Mil. Rapid Dose Therapeutics's Total Assets for the quarter that ended in Aug. 2025 was $3.08 Mil. Therefore, Rapid Dose Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Nov. 2025 was -0.16.
Rapid Dose Therapeutics Scaled Net Operating Assets Related Terms
Rapid Dose Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Rapid Dose Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics Scaled Net Operating Assets Chart
RDTCF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Rapid Dose Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -0.16 mean?
Rapid Dose Therapeutics (RDTCF) has a Scaled Net Operating Assets of -0.16 as of Nov. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' Scaled Net Operating Assets too high?
Rapid Dose Therapeutics' current Scaled Net Operating Assets is -0.16. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Scaled Net Operating Assets compare to VRTX and REGN?
Rapid Dose Therapeutics' Scaled Net Operating Assets of -0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Scaled Net Operating Assets is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Scaled Net Operating Assets is -0.16. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Scaled Net Operating Assets is -0.16 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
Scaled Net Operating Assets: -0.16
GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score
Get the complete analysis for RDTCF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
